AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
A pharmacokinetics and pharmacogenetics study to complement the current knowledge of
tacrolimus prolonged release (Advagraf®) in the immediate post-transplantation period and at
steady-state (M3 post transplantation) and to improve the optimal dose of Advagraf® based on
tacrolimus AUC estimated by two Limited Samples Strategies during the first 3 months after
renal transplantation.
Data obtained with tacrolimus prolonged release will be compared with those of tacrolimus
immediate release (Prograf®)